Key result
Aprotinin administration increased median ADP-mediated platelet aggregation from 84% to 94% (P<0.01) in clopidogrel-treated patients with acute coronary syndrome undergoing coronary surgery.
Why the study?
Does aprotinin reduce the antiplatelet effect of clopidogrel in patients with acute coronary syndrome undergoing coronary surgery?
Does aprotinin reduce the antiplatelet effect of clopidogrel in patients with acute coronary syndrome undergoing coronary surgery?
Absolute Event Rate: 94% vs 84%
p-value: p=<0.01
Aprotinin significantly increases ADP-induced platelet aggregation in clopidogrel-treated patients undergoing coronary surgery, reducing relative platelet inhibition by >50%.
Aprotinin was associated with reduced clopidogrel effect in ACS surgery; leaves open impact on bleeding or transfusion needs.
Aprotinin reduces bleeding and transfusion rates in patients undergoing coronary surgery while on clopidogrel. However, safety studies have indicated that aprotinin may have a possible adverse effect related to an increased incidence of thromboembolic events. We therefore studied the adenosinediphosphate (ADP) mediated platelet aggregation before and after administration of aprotinin in patients on clopidogrel. Fifteen clopidogrel-treated patients with acute coronary syndrome undergoing coronary surgery were studied. ADP-mediated platelet aggregation and platelet count ratio (%) were measured before and after a bolus dose [2 x 10(6) kallikrein inhibiting units (KIU)] of aprotinin. Aprotinin induced an increased aggregation in 11 of 15 patients (73%), and a decrease was registered in two patients (13%). The median (25th/75th percentile) ADP-mediated platelet aggregation before and after aprotinin was 84% (76/91) and 94% (86/97, P<0.01). Clopidogrel non-responders with >90% aggregation (n=4) had a median aggregation of 94.5% (91.5/97.5) vs. 82% (73/87, P<0.01) in the responders (n=11). The median increase in platelet aggregation after aprotinin was 8% (5/20) in the responders vs. 0% (-5.25/3, P<0.01) in the non-responders. Aprotinin increased ADP induced platelet aggregation from 84 to 94% in patients on clopidogrel, which corresponds to a median decrease in relative platelet inhibition of >50%.
No takes yet. Share an insight, caveat, or question.
Lindvall et al. (2009) studied Acute coronary syndrome (n=15). Aprotinin vs. Baseline (before aprotinin administration) was evaluated on ADP-mediated platelet aggregation (p=<0.01). Aprotinin administration increased median ADP-mediated platelet aggregation from 84% to 94% (P<0.01) in clopidogrel-treated patients with acute coronary syndrome undergoing coronary surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: